Your browser is no longer supported. Please, upgrade your browser.
PGEN Precigen, Inc. daily Stock Chart
Precigen, Inc.
Index- P/E- EPS (ttm)-1.13 Insider Own1.30% Shs Outstand160.34M Perf Week8.18%
Market Cap850.80M Forward P/E- EPS next Y-0.54 Insider Trans-15.62% Shs Float143.85M Perf Month5.78%
Income-175.40M PEG- EPS next Q-0.14 Inst Own73.10% Short Float20.28% Perf Quarter50.16%
Sales97.20M P/S8.75 EPS this Y57.60% Inst Trans-2.04% Short Ratio14.78 Perf Half Y3.59%
Book/sh0.54 P/B8.81 EPS next Y10.00% ROA-59.90% Target Price- Perf Year-36.45%
Cash/sh0.83 P/C5.71 EPS next 5Y2.40% ROE-190.60% 52W Range1.26 - 7.80 Perf YTD-13.14%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-69.70% 52W High-37.69% Beta1.64
Dividend %- Quick Ratio2.50 Sales past 5Y4.80% Gross Margin38.70% 52W Low285.71% ATR0.33
Employees770 Current Ratio2.70 Sales Q/Q31.90% Oper. Margin- RSI (14)56.88 Volatility7.99% 7.18%
OptionableYes Debt/Eq2.54 EPS Q/Q44.50% Profit Margin- Rel Volume0.21 Prev Close4.76
ShortableYes LT Debt/Eq2.16 EarningsMay 06 AMC Payout- Avg Volume1.97M Price4.86
Recom2.30 SMA207.39% SMA5012.94% SMA20011.21% Volume132,076 Change2.10%
May-08-20Initiated H.C. Wainwright Buy $5
Aug-06-20 07:30AM  
Aug-03-20 07:30AM  
Jun-22-20 08:45AM  
Jun-11-20 07:30AM  
Jun-10-20 09:35AM  
Jun-04-20 04:05PM  
May-21-20 02:27PM  
May-15-20 07:30AM  
Apr-29-20 07:30AM  
Apr-20-20 07:36AM  
Mar-02-20 04:05PM  
Feb-24-20 07:30AM  
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sabzevari HelenPresident and CEOJul 20Sale4.5812,22055,968402,145Jul 21 06:40 PM
Frank StevenDirectorJun 30Option Exercise3.172,9689,409265,563Jul 06 04:22 PM
ALVAREZ CESAR LDirectorJun 23Option Exercise3.172,9689,409184,133Jun 25 04:22 PM
MITCHELL DEAN JDirectorJun 19Option Exercise3.172,9689,409105,441Jun 23 04:57 PM
Lehr Donald P.Chief Legal OfficerJun 16Sale4.508,42837,926231,558Jun 17 04:35 PM
Perez Jeffrey ThomasSVP, IP AffairsJun 16Sale4.507,61934,286225,889Jun 17 04:32 PM
Sterling Rick L.Chief Financial OfficerJun 16Sale4.507,61934,286287,973Jun 17 04:32 PM
Lehr Donald P.Chief Legal OfficerMay 18Sale2.3662,895148,659214,986May 19 04:33 PM
Sterling Rick L.Chief Financial OfficerMay 18Sale2.3656,853134,372270,592May 19 04:34 PM
Perez Jeffrey ThomasSVP, IP AffairsMay 18Sale2.3656,853134,372208,508May 19 04:33 PM
Sabzevari HelenPresident and CEOMay 15Sale2.37217,527515,800389,365May 18 04:04 PM